DNA, gut microbiome and blood, read as one reasoned profile under your hospital's brand. From hereditary-risk programmes in oncology to pharmacogenomics and executive health — TGB's platform, lab partnerships and evidence engine, integrated with the LIS/EHR you already run. We handle the science. You own the patient relationship.
The Gene Box gives hospitals and clinics white-label multi-omic reports — DNA, microbiome and blood read as one decision-support profile — delivered into the LIS/EHR they already run via HL7/FHIR, without building a bioinformatics team.
Evolveme fuses the layers into one reasoned profile: every interpretation traces to a curated evidence base of 150,000 references, and a qualified human signs off before a report reaches a clinician.
Decision-support, not diagnosis — the treating clinician stays in charge. Reports carry your hospital's brand: TGB is a B2B platform, and your patients reach it only through you. Founded in Mumbai in 2015; 39 partners across India and 10 other countries.
Patients asking for genetic testing but your lab doesn't offer it
Oncology needs hereditary cancer screening — building in-house takes 18+ months
PGx could reduce adverse drug events but there's no integration with your pharmacy workflow
Competitors are marketing 'precision health' and you're falling behind
No internal bioinformatics team to interpret raw genomic data
Regulatory complexity around genetic counselling requirements
We don't sell you everything at once. Here's the stack built for your specific needs — from entry point to full platform.
Lead with clinical genomics — 18 cancers, 3,000+ rare diseases, PGx. Highest clinical seriousness builds trust for the entire brand.
Universal entry — AI overlay on blood work you already do. Zero capex. Gets genomics into every department at $3-5/report.
Wellness wing expansion — longevity, nutrigenomics, sports for your preventive care and executive health programmes.
Platform layer — integrates into your LIS/EHR via HL7/FHIR. White-label reports. Genetic counselling summaries auto-generated.
Multi-omic decision-support for the people who run clinical programmes, and the CXOs deciding whether to build or buy.
API path: REST + JSON with webhook callbacks when reports are ready, and HL7/FHIR R4-compatible exchange for EHR and LIS integration. Platform path: the full white-label Evolveme platform under your hospital's brand, with your patient-facing experience.
Either way, five omic layers resolve into one reasoned profile backed by 150,000 curated references and 1,200+ validated biomarkers — recommended by Illumina and ThermoFisher, ISO 9001:2015 certified, GDPR compliant.
Revenue model: per-test pricing with volume tiers, plus a platform fee for LIS integration and white-label deployment. New service-line revenue accrues to the hospital; interpretation is priced from roughly $3–5 per report on top of the lab work you already do.
Map your service lines, patient volumes, and clinical priorities.
Select the right product mix and integration approach for your LIS.
Launch with one department. Validate workflows and measure outcomes.
Expand across departments, add products, train clinical teams.
Map your service lines, patient volumes, and clinical priorities.
Select the right product mix and integration approach for your LIS.
Launch with one department. Validate workflows and measure outcomes.
Expand across departments, add products, train clinical teams.
5-10% of ALL cancers are hereditary. Offering hereditary cancer gene panels + PGx = the highest clinical seriousness service — which makes it the highest trust builder for the whole hospital brand. TGB is recommended by Illumina and ThermoFisher, holds a 5-year MOU for 10,000 Olympic athletes, and operates across 39 partners in 11 countries.
See a live demo tailored to your exact use case and patient volume.
